Key facts
- Vivacelle Bio’s last known valuation is $70.0M (Oct 2025).
- It has raised $27.5M; the latest was Later Stage VC ($20.0M) in Oct 2025.
- Notable investors include National Institutes of Health, 2Flo Ventures, U.S. Navy.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Vivacelle Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Vivacelle Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vivacelle Bio
Developer of a novel intravenous resuscitation fluid technology designed to reverse the consequences of hypovolemia and shock. The company uses technology to produce a colloid composed of phospholipid nanoparticles that expand the volume, redistribute nitric oxide, and protect against reperfusion injury, enabling healthcare professionals to treat various medical conditions.
- Sector
- Healthcare
- HQ
- Kansas City, MO, United States
- Founded
- 2013
- Employees
- 4
- Website
- vivacellebio.com/
- Ownership
- Privately Held (backing)
Vivacelle Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vivacelle Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vivacelle Bio in its N-PORT filings yet. We sweep new filings monthly.